Figure 5.
Proangiogenic and pro-inflammatory characterization of AFT-ADMSC-GFP: (a,b) immunohistochemistry for CD31 in the AFT samples (upper panel and inset) and in the AFT-ADMSC-GFP grafts (bottom panel and inset) at 7 days and 60 days after transplantation; (c,d) quantitative measurement of CD31-positive vessels for the AFT and AFT-ADMSC-GFP specimens, * p < 0.05; (e,f) immunohistochemistry for F4/80 in the AFT samples (upper panel and inset) and in the AFT-ADMSC-GFP grafts (bottom panel and inset) at 7 days and 60 days after transplantation; (g,h) quantification of the F4/80-positive area/graft, respectively, at 7 days and 60 days post-engraftment performed using Image J software (NIH), * p < 0.05; n = 7. Scale bar = 100 µm.
